Story updated at 9:55 a.m. to reflect market activity.
Express Scripts gained 0.4% to $66.60 in morning trading.
The analyst firm reiterated its "buy" rating for the company. Express Scripts' lack major mail order generic launches and generic inflation headwinds "may have served as negative offsets" according to UBS analyst Steven Valiquette.
"These may have prompted some PBMs such as ESRX to exercise 'MAC' clauses with retailer dispensers in an effort to lower COGS during 2Q," Valiquette wrote. "Separately, there has been much discussion about recent insider selling at ESRX. We believe if there is any negative signal here, it would have more to do with 2015 than 2014 given the selling season trends. Further, ESRX has already lowered 2014 guidance, and would not seem operationally to need to do it again (unless somehow buybacks are not achieved)."
Must read: Warren Buffett's 25 Favorite Stocks
Separately, TheStreet Ratings team rates EXPRESS SCRIPTS HOLDING CO as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:
"We rate EXPRESS SCRIPTS HOLDING CO (ESRX) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself."